TCGA-E7-A6MF-01A-12R-A32O-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 24.63863338
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- WNT_BETA_CATENIN_SIGNALING+0.340
- TGF_BETA_SIGNALING+0.180
- HEME_METABOLISM+0.160
- P53_PATHWAY+0.150
- PANCREAS_BETA_CELLS+0.110
- BILE_ACID_METABOLISM+0.070
- HEDGEHOG_SIGNALING+0.060
- KRAS_SIGNALING_DN+0.060
- APICAL_SURFACE+0.030
- ESTROGEN_RESPONSE_EARLY+0.030
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.610
- E2F_TARGETS-0.600
- MYC_TARGETS_V2-0.540
- MTORC1_SIGNALING-0.510
- G2M_CHECKPOINT-0.480
- TNFA_SIGNALING_VIA_NFKB-0.480
- ANGIOGENESIS-0.460
- IL6_JAK_STAT3_SIGNALING-0.440
- MYC_TARGETS_V1-0.440
- ALLOGRAFT_REJECTION-0.420
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1516060 | — | — | 0.910 |
| 2 | SRR12475149 | — | — | 0.899 |
| 3 | C3N-03420 | — | cohortA1 | 0.896 |
| 4 | SRR11296800 | — | — | 0.889 |
| 5 | eb67b977-b299-4bbc-b3f6-25d516473405 | — | — | 0.883 |
| 6 | SRR650199 | — | — | 0.881 |
| 7 | SRR1313106 | — | B | 0.876 |
| 8 | SRR1516046 | — | — | 0.875 |
| 9 | SRR1516063 | — | — | 0.873 |
| 10 | SRR23303736 | — | — | 0.870 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| WNT_BETA_CATENIN_SIGNALING | 0.340 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.180 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.160 | Temsirolimus | — uncovered |
| P53_PATHWAY | 0.150 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.110 | Cobimetinib | — uncovered |
| BILE_ACID_METABOLISM | 0.070 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.060 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.060 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.030 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.030 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.020 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.010 | Inavolisib | — uncovered |